A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)

Phase 2

Completed

• Conditions: Generalized Anxiety Disorder
• Interventions: Drug: MK0777; Drug: Placebo (unspecified)

• Registration Number: NCT00703833
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The study will look at the effectiveness of MK0777 in patients with Generalized Anxiety Disorder.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-09
• Primary Completion: 2003-02
• Study Completion: 2003-02
• Study First Submitted: 2008-06-22
• Study First Submitted QC: 2008-06-23
• Study First Posted: 2008-06-24
• Status Verified: 2015-10
• Last Update Submitted: 2015-10-30
• Last Update Posted: 2015-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

• Male or Female
• Current diagnosis of Generalized Anxiety Disorder
• Age 18 - 70

Read More

Exclusion Criteria

• Women who are pregnant, or breast-feeding
• Use of illicit drugs
• History of drug or alcohol dependence

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	MK0777	Drug
2	Placebo (unspecified)	Placebo

Primary Outcome Measures

Name	Time	Method
Measure the reduction of anxiety	after 4 weeks and at end of study

Secondary Outcome Measures

Name	Time	Method
Safety and efficacy	throughout study and at end of study